Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Initiation
Lineage Cell Therapeutics initiated with an Outperform at Noble Capital » 08:18
09/17/20
09/17
08:18
09/17/20
08:18
LCTX

Lineage Cell Therapeutics

$1.06 /

+0.1022 (+10.67%)

Noble Capital analyst Ahu…

Noble Capital analyst Ahu Demir initiated coverage of Lineage Cell Therapeutics with an Outperform rating. From its pipeline, OpRegen - a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration - and VAC2 - an allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer - may be nearing value inflections that "could be transformational," Demir stated.

ShowHide Related Items >><<
LCTX Lineage Cell Therapeutics
$1.06 /

+0.1022 (+10.67%)

LCTX Lineage Cell Therapeutics
$1.06 /

+0.1022 (+10.67%)

08/31/20 H.C. Wainwright
Lineage Cell extends cash runway to over two years, says H.C. Wainwright
06/09/20 H.C. Wainwright
Lineage Cell Therapeutics price target raised to $7 from $4 at H.C. Wainwright
06/01/20 H.C. Wainwright
Lineage Cell evidence 'preliminary,' but 'unprecedented,' says H.C. Wainwright
05/06/20 H.C. Wainwright
Lineage update shows OpRegen 'nicely on track,' says H.C. Wainwright
LCTX Lineage Cell Therapeutics
$1.06 /

+0.1022 (+10.67%)

Hot Stocks
Lineage Cell Therapeutics, AgeX Therapeutics expand ESI stem cell line agreement » 08:07
09/09/20
09/09
08:07
09/09/20
08:07
LCTX

Lineage Cell Therapeutics

$0.89 /

+0.0243 (+2.80%)

, AGE

AgeX Therapeutics

$0.79 /

-0.005 (-0.63%)

Lineage Cell Therapeutics…

Lineage Cell Therapeutics (LCTX), ES Cell International, a subsidiary of Lineage, and AgeX Therapeutics (AGE) announced the broadening of their collaborative relationship with regard to ESI stem cell lines. ESI cell lines are current Good Manufacturing Practice-compatible, registered with the National Institutes of Health and widely studied as a potential source for the industrial-scale manufacture of any cell type in the human body. Neither party made or received any cash payments in connection with this arrangement.

ShowHide Related Items >><<
LCTX Lineage Cell Therapeutics
$0.89 /

+0.0243 (+2.80%)

AGE AgeX Therapeutics
$0.79 /

-0.005 (-0.63%)

LCTX Lineage Cell Therapeutics
$0.89 /

+0.0243 (+2.80%)

08/31/20 H.C. Wainwright
Lineage Cell extends cash runway to over two years, says H.C. Wainwright
06/09/20 H.C. Wainwright
Lineage Cell Therapeutics price target raised to $7 from $4 at H.C. Wainwright
06/01/20 H.C. Wainwright
Lineage Cell evidence 'preliminary,' but 'unprecedented,' says H.C. Wainwright
05/06/20 H.C. Wainwright
Lineage update shows OpRegen 'nicely on track,' says H.C. Wainwright
AGE AgeX Therapeutics
$0.79 /

-0.005 (-0.63%)

LCTX Lineage Cell Therapeutics
$0.89 /

+0.0243 (+2.80%)

Hot Stocks
Lineage Cell Therapeutics awarded $573,000 grant from IIA for bio-retinal patch » 08:25
09/08/20
09/08
08:25
09/08/20
08:25
LCTX

Lineage Cell Therapeutics

$0.87 /

-0.022 (-2.47%)

Lineage Cell Therapeutics…

Lineage Cell Therapeutics announced that the company has been awarded a new research & development grant of up to 1.95M Israeli New Shekels, or approximately $573,000, from the Israel Innovation Authority, or IIA. The grant, which is one of the first under the IIA's bio-convergence initiative, provides funding for the development of a novel bio-retinal patch for the treatment of retinal diseases by Lineage's subsidiary, Cell Cure Neurosciences, in partnership with Precise Bio.

ShowHide Related Items >><<
LCTX Lineage Cell Therapeutics
$0.87 /

-0.022 (-2.47%)

LCTX Lineage Cell Therapeutics
$0.87 /

-0.022 (-2.47%)

08/31/20 H.C. Wainwright
Lineage Cell extends cash runway to over two years, says H.C. Wainwright
06/09/20 H.C. Wainwright
Lineage Cell Therapeutics price target raised to $7 from $4 at H.C. Wainwright
06/01/20 H.C. Wainwright
Lineage Cell evidence 'preliminary,' but 'unprecedented,' says H.C. Wainwright
05/06/20 H.C. Wainwright
Lineage update shows OpRegen 'nicely on track,' says H.C. Wainwright
LCTX Lineage Cell Therapeutics
$0.87 /

-0.022 (-2.47%)

Conference/Events
LD Micro to hold a virtual conference » 08:18
09/01/20
09/01
08:18
09/01/20
08:18
FRHC

Freedom Holding

$23.77 /

+0.26 (+1.11%)

, ISDR

Issuer Direct

$17.14 /

+0.74 (+4.51%)

, INFU

InfuSystem

$14.56 /

+0.48 (+3.41%)

, ALLT

Allot Ltd.

$10.50 /

-0.07 (-0.66%)

, NEPH

Nephros

$6.51 /

-0.26 (-3.84%)

, VUZI

Vuzix

$3.74 /

-0.105 (-2.73%)

, SLGG

Super League Gaming

$1.83 /

-0.03 (-1.61%)

, BLGO

BioLargo

$0.00 /

+ (+0.00%)

, DRAD

Digirad Corp

$2.52 /

-0.035 (-1.37%)

, HGBL

Heritage Global

$3.75 /

+ (+0.00%)

, SOTK

Sono-Tek

$0.00 /

+ (+0.00%)

, LCTX

Lineage Cell Therapeutics

$0.91 /

+0.0133 (+1.48%)

, CTXR

Citius Pharmaceuticals

$0.93 /

-0.032 (-3.33%)

, BLU

Bellus Health

$2.48 /

-0.03 (-1.20%)

, ARTL

Artelo Biosciences

$0.96 /

-0.035 (-3.52%)

, CSSE

Chicken Soup for the Soul

$15.22 /

-0.54 (-3.43%)

, USAU

U.S. Gold

$10.40 /

-0.57 (-5.20%)

LD 500 Investor Virtual…

LD 500 Investor Virtual Conference will be held on September 1-4 with presentations to begin on September 1 at 8:40 am. Webcast Link

ShowHide Related Items >><<
VUZI Vuzix
$3.74 /

-0.105 (-2.73%)

USAU U.S. Gold
$10.40 /

-0.57 (-5.20%)

SOTK Sono-Tek
$0.00 /

+ (+0.00%)

SLGG Super League Gaming
$1.83 /

-0.03 (-1.61%)

NEPH Nephros
$6.51 /

-0.26 (-3.84%)

LCTX Lineage Cell Therapeutics
$0.91 /

+0.0133 (+1.48%)

ISDR Issuer Direct
$17.14 /

+0.74 (+4.51%)

INFU InfuSystem
$14.56 /

+0.48 (+3.41%)

FRHC Freedom Holding
$23.77 /

+0.26 (+1.11%)

DRAD Digirad Corp
$2.52 /

-0.035 (-1.37%)

CTXR Citius Pharmaceuticals
$0.93 /

-0.032 (-3.33%)

CSSE Chicken Soup for the Soul
$15.22 /

-0.54 (-3.43%)

BLU Bellus Health
$2.48 /

-0.03 (-1.20%)

BLGO BioLargo
$0.00 /

+ (+0.00%)

ARTL Artelo Biosciences
$0.96 /

-0.035 (-3.52%)

FRHC Freedom Holding
$23.77 /

+0.26 (+1.11%)

ISDR Issuer Direct
$17.14 /

+0.74 (+4.51%)

08/25/20 Northland
Issuer Direct price target raised to $18 from $16 at Northland
INFU InfuSystem
$14.56 /

+0.48 (+3.41%)

08/31/20
Fly Intel: Top five analyst initiations
08/31/20 Craig-Hallum
InfuSystem initiated with a Buy at Craig-Hallum
06/09/20 Lake Street
InfuSystem initiated with a Buy at Lake Street
ALLT Allot Ltd.
$10.50 /

-0.07 (-0.66%)

04/22/20 Lake Street
Allot Ltd. initiated with a Buy at Lake Street
02/03/20 Needham
Allot Communications price target raised to $11.50 from $9.50 at Needham
NEPH Nephros
$6.51 /

-0.26 (-3.84%)

01/06/20 Benchmark
Benchmark names Alibaba, Nvidia, Comcast among best ideas for first half
10/24/19 Benchmark
Nephros initiated with a Speculative Buy at Benchmark
10/04/19 Maxim
Nephros initiated with a Buy rating at Maxim
VUZI Vuzix
$3.74 /

-0.105 (-2.73%)

05/11/20 Alliance Global Partners
Vuzix downgraded to Neutral from Buy at Alliance Global Partners
SLGG Super League Gaming
$1.83 /

-0.03 (-1.61%)

05/29/20 Alliance Global Partners
Super League Gaming initiated with a Buy at Alliance Global Partners
03/02/20 Northland
Super League Gaming price target lowered to $8 from $15 at Northland
01/14/20 Stephens
Super League Gaming's Wanda partnership could be top-line driver, says Stephens
12/17/19 Stephens
Super League Gaming initiated with an Equal Weight at Stephens
BLGO BioLargo
$0.00 /

+ (+0.00%)

03/03/20
LD Micro to hold a virtual conference
DRAD Digirad Corp
$2.52 /

-0.035 (-1.37%)

HGBL Heritage Global
$3.75 /

+ (+0.00%)

SOTK Sono-Tek
$0.00 /

+ (+0.00%)

01/23/20
Fly Intel: Top analyst initiations
01/23/20
Sono-Tek initiated with a Buy at Dougherty
LCTX Lineage Cell Therapeutics
$0.91 /

+0.0133 (+1.48%)

08/31/20 H.C. Wainwright
Lineage Cell extends cash runway to over two years, says H.C. Wainwright
06/09/20 H.C. Wainwright
Lineage Cell Therapeutics price target raised to $7 from $4 at H.C. Wainwright
06/01/20 H.C. Wainwright
Lineage Cell evidence 'preliminary,' but 'unprecedented,' says H.C. Wainwright
05/06/20 H.C. Wainwright
Lineage update shows OpRegen 'nicely on track,' says H.C. Wainwright
CTXR Citius Pharmaceuticals
$0.93 /

-0.032 (-3.33%)

BLU Bellus Health
$2.48 /

-0.03 (-1.20%)

08/14/20 H.C. Wainwright
Bellus Health price target lowered to $10 from $28 at H.C. Wainwright
07/07/20 Guggenheim
Guggenheim downgrades Bellus Health to Neutral after 'disappointing' cough trial
07/07/20 Guggenheim
Bellus Health downgraded to Neutral from Buy at Guggenheim
07/06/20 Jefferies
Jefferies cuts Bellus target to $6, sees potential for 'meaningful upside'
ARTL Artelo Biosciences
$0.96 /

-0.035 (-3.52%)

05/13/20 Maxim
Artelo Biosciences downgraded to Hold from Buy at Maxim
CSSE Chicken Soup for the Soul
$15.22 /

-0.54 (-3.43%)

08/14/20 DA Davidson
Chicken Soup for the Soul price target raised to $28 from $23 at DA Davidson
02/24/20 DA Davidson
Chicken Soup for the Soul initiated with a Buy at DA Davidson
10/24/19 National Securities
Chicken Soup for the Soul initiated with a Buy at National Securities
USAU U.S. Gold
$10.40 /

-0.57 (-5.20%)

07/13/20 H.C. Wainwright
U.S. Gold price target raised to $16.50 from $14.50 at H.C. Wainwright
VUZI Vuzix
$3.74 /

-0.105 (-2.73%)

SLGG Super League Gaming
$1.83 /

-0.03 (-1.61%)

NEPH Nephros
$6.51 /

-0.26 (-3.84%)

LCTX Lineage Cell Therapeutics
$0.91 /

+0.0133 (+1.48%)

DRAD Digirad Corp
$2.52 /

-0.035 (-1.37%)

CSSE Chicken Soup for the Soul
$15.22 /

-0.54 (-3.43%)

ARTL Artelo Biosciences
$0.96 /

-0.035 (-3.52%)

ALLT Allot Ltd.
$10.50 /

-0.07 (-0.66%)

  • 27
    Aug
  • 31
    Jan
  • 05
    Sep
ARTL Artelo Biosciences
$0.96 /

-0.035 (-3.52%)

CSSE Chicken Soup for the Soul
$15.22 /

-0.54 (-3.43%)

BLU Bellus Health
$2.48 /

-0.03 (-1.20%)

VUZI Vuzix
$3.74 /

-0.105 (-2.73%)

ALLT Allot Ltd.
$10.50 /

-0.07 (-0.66%)

Recommendations
Lineage Cell extends cash runway to over two years, says H.C. Wainwright » 10:35
08/31/20
08/31
10:35
08/31/20
10:35
LCTX

Lineage Cell Therapeutics

$0.93 /

+0.0301 (+3.34%)

, AGE

AgeX Therapeutics

$0.91 /

-0.045 (-4.74%)

H.C. Wainwright analyst…

H.C. Wainwright analyst Joseph Pantginis noted that Lineage Cell Therapeutics (LCTX) received $24.6M in cash from privately-held Juvenescence from the outstanding principal and interest from a note issued by Lineage in August 2018 for the sale of 14.4M shares of AgeX Therapeutics (AGE). With today's cash infusion, the company now has a cash runway for over two years, said Pantginis, who sees the payment as a continuation of Lineage's "strong track record of non-dilutive funding." He reiterates a Buy rating and $7 price target on Lineage Cell shares.

ShowHide Related Items >><<
LCTX Lineage Cell Therapeutics
$0.93 /

+0.0301 (+3.34%)

AGE AgeX Therapeutics
$0.91 /

-0.045 (-4.74%)

LCTX Lineage Cell Therapeutics
$0.93 /

+0.0301 (+3.34%)

06/09/20 H.C. Wainwright
Lineage Cell Therapeutics price target raised to $7 from $4 at H.C. Wainwright
06/01/20 H.C. Wainwright
Lineage Cell evidence 'preliminary,' but 'unprecedented,' says H.C. Wainwright
05/06/20 H.C. Wainwright
Lineage update shows OpRegen 'nicely on track,' says H.C. Wainwright
AGE AgeX Therapeutics
$0.91 /

-0.045 (-4.74%)

LCTX Lineage Cell Therapeutics
$0.93 /

+0.0301 (+3.34%)

Hot Stocks
Lineage Cell Therapeutics receives $24.6M payment from Juvenescence » 09:27
08/31/20
08/31
09:27
08/31/20
09:27
LCTX

Lineage Cell Therapeutics

$0.90 /

+0.0299 (+3.43%)

Lineage Cell Therapeutics…

Lineage Cell Therapeutics said in a release, "Lineage Cell Therapeutics announced it received $24.6 million in cash from Juvenescence Ltd., representing principal and interest due under a convertible promissory note. The note was issued in August 2018 as partial payment for the sale by Lineage to Juvenescence of 14.4 million shares of common stock of AgeX Therapeutics, Inc."

ShowHide Related Items >><<
LCTX Lineage Cell Therapeutics
$0.90 /

+0.0299 (+3.43%)

LCTX Lineage Cell Therapeutics
$0.90 /

+0.0299 (+3.43%)

06/09/20 H.C. Wainwright
Lineage Cell Therapeutics price target raised to $7 from $4 at H.C. Wainwright
06/01/20 H.C. Wainwright
Lineage Cell evidence 'preliminary,' but 'unprecedented,' says H.C. Wainwright
05/06/20 H.C. Wainwright
Lineage update shows OpRegen 'nicely on track,' says H.C. Wainwright
LCTX Lineage Cell Therapeutics
$0.90 /

+0.0299 (+3.43%)

Over a month ago
Earnings
Lineage Cell Therapeutics reports Q2 EPS (4c), consensus (4c) » 16:53
08/06/20
08/06
16:53
08/06/20
16:53
LCTX

Lineage Cell Therapeutics

$0.92 /

+0.0465 (+5.34%)

Reports Q2 revenue…

Reports Q2 revenue $386,000, consensus $560,000. "Lineage has continued to make significant progress across our entire cell therapy pipeline, with positive milestones on each of our three programs announced this quarter," stated Brian M. Culley, Lineage CEO. "Most importantly, after moving into a cohort of patients with less advanced disease, we reported the first known finding of retinal tissue restoration, which we believe could become a landmark discovery in the treatment of dry AMD. Specifically, Lineage reported evidence of substantial anatomical restoration of retinal tissue within an area of geographic atrophy, or GA. The area of GA was approximately 25% smaller when assessed at 9 months, compared to the patient's pre-treatment baseline. These findings were initially discovered by an independent external advisor using multiple imaging technologies and were subsequently confirmed by the reading center and additional experts in the field of retinal imaging. In light of the significance of this finding, our objective is to treat and monitor the final three patients in Cohort 4 of our dry AMD study and seek to demonstrate additional evidence of this exciting finding. These data also will direct our clinical, regulatory, and ongoing partnership discussions."

ShowHide Related Items >><<
LCTX Lineage Cell Therapeutics
$0.92 /

+0.0465 (+5.34%)

LCTX Lineage Cell Therapeutics
$0.92 /

+0.0465 (+5.34%)

06/09/20 H.C. Wainwright
Lineage Cell Therapeutics price target raised to $7 from $4 at H.C. Wainwright
06/01/20 H.C. Wainwright
Lineage Cell evidence 'preliminary,' but 'unprecedented,' says H.C. Wainwright
05/06/20 H.C. Wainwright
Lineage update shows OpRegen 'nicely on track,' says H.C. Wainwright
LCTX Lineage Cell Therapeutics
$0.92 /

+0.0465 (+5.34%)

Hot Stocks
Lineage Cell Therapeutics receives extension of development grant for OpRegen » 08:18
07/06/20
07/06
08:18
07/06/20
08:18
LCTX

Lineage Cell Therapeutics

$0.79 /

-0.0364 (-4.42%)

Lineage Cell Therapeutics…

Lineage Cell Therapeutics announced that as a result of continued clinical progress, the Israel Innovation Authority, or IIA, has extended its previously awarded development grant in support of OpRegen, the company's retinal pigment epithelium, or RPE, cell transplant therapy in development for the treatment of dry age-related macular degeneration, or AMD. The research & development grant of up to 9M Israeli New Shekels, or approximately $2.5M was awarded in 2019 by the IIA and has been extended for use through June 2021 based on promising clinical data from the ongoing Phase 1/2a clinical study of OpRegen. The IIA has provided annual grants totaling approximately $16M for the development of the OpRegen program so far.

ShowHide Related Items >><<
LCTX Lineage Cell Therapeutics
$0.79 /

-0.0364 (-4.42%)

LCTX Lineage Cell Therapeutics
$0.79 /

-0.0364 (-4.42%)

06/09/20 H.C. Wainwright
Lineage Cell Therapeutics price target raised to $7 from $4 at H.C. Wainwright
06/01/20 H.C. Wainwright
Lineage Cell evidence 'preliminary,' but 'unprecedented,' says H.C. Wainwright
05/06/20 H.C. Wainwright
Lineage update shows OpRegen 'nicely on track,' says H.C. Wainwright
LCTX Lineage Cell Therapeutics
$0.79 /

-0.0364 (-4.42%)

Over a quarter ago
Hot Stocks
Lineage Cell Therapeutics provides OPC1 update » 08:06
06/25/20
06/25
08:06
06/25/20
08:06
LCTX

Lineage Cell Therapeutics

$0.93 /

-0.0339 (-3.50%)

Lineage Cell Therapeutics…

Lineage Cell Therapeutics provided an update on OPC1, the company's oligodendrocyte progenitor cell, or OPC, therapy for the treatment of acute spinal cord injury, or SCI. The OPC1 program was obtained through Lineage's acquisition of Asterias Biopharmaceuticals in March 2019, and manufacturing has been completely transferred to the company's current good manufacturing practice, or cGMP, facility in Israel, where key process improvements have been developed and implemented. Lineage also has strengthened its patent position in order to protect the OPC1 processes, product and composition, and methods of use. Lineage intends to meet with the FDA to discuss further development of the OPC1 program by the end of 2020. The company plans on having a meeting with the FDA to discuss manufacturing improvements and the design of a late-stage comparative clinical trial; In 2020, the company will Introduce a new "thaw-and-inject" formulation to enable preparation and administration of cells to the spinal cord, avoiding the need for washing and other dose preparation steps one day prior to treatment and improving commercial positioning. Lastly, Lineage expects to Identify a novel delivery system, to make the surgical procedure more compatible with a thaw and inject formulation of OPC1, improving overall end-user experience for the surgeon.

ShowHide Related Items >><<
LCTX Lineage Cell Therapeutics
$0.93 /

-0.0339 (-3.50%)

LCTX Lineage Cell Therapeutics
$0.93 /

-0.0339 (-3.50%)

06/09/20 H.C. Wainwright
Lineage Cell Therapeutics price target raised to $7 from $4 at H.C. Wainwright
06/01/20 H.C. Wainwright
Lineage Cell evidence 'preliminary,' but 'unprecedented,' says H.C. Wainwright
05/06/20 H.C. Wainwright
Lineage update shows OpRegen 'nicely on track,' says H.C. Wainwright
LCTX Lineage Cell Therapeutics
$0.93 /

-0.0339 (-3.50%)

Hot Stocks
Lineage Cell Therapeutics reinitiates patient enrollment in OpRegen study » 08:17
06/18/20
06/18
08:17
06/18/20
08:17
LCTX

Lineage Cell Therapeutics

$1.06 /

+0.045 (+4.43%)

Lineage Cell Therapeutics…

Lineage Cell Therapeutics announced that it has restarted patient enrollment in a Phase 1/2a clinical study of its lead product candidate, OpRegen, a retinal pigment epithelium, or RPE, cell transplant therapy currently in development for the treatment of dry age-related macular degeneration, or AMD, following a temporary pause in enrollment as a result of the COVID-19 pandemic. The company said in a release, "The first patient dosed in the re-start was at Cincinnati Eye Institute, or CEI, under the direction of principal investigator Christopher D. Riemann, M.D., Vitreoretinal Surgeon and Fellowship Director, CEI and University of Cincinnati School of Medicine. CEI is a global leader in ophthalmology research and a clinical site where local health and safety regulations recently enabled and cleared clinical study recruitment and treatment. The patient enrolled at CEI was administered Lineage's new thaw-and-inject formulation of OpRegen with Gyroscope Therapeutics' Orbit Subretinal Delivery System. The Company anticipates that it will complete enrollment of the last 3 patients in Cohort 4 of the OpRegen clinical study in the third quarter of 2020."

ShowHide Related Items >><<
LCTX Lineage Cell Therapeutics
$1.06 /

+0.045 (+4.43%)

LCTX Lineage Cell Therapeutics
$1.06 /

+0.045 (+4.43%)

06/09/20 H.C. Wainwright
Lineage Cell Therapeutics price target raised to $7 from $4 at H.C. Wainwright
06/01/20 H.C. Wainwright
Lineage Cell evidence 'preliminary,' but 'unprecedented,' says H.C. Wainwright
05/06/20 H.C. Wainwright
Lineage update shows OpRegen 'nicely on track,' says H.C. Wainwright
LCTX Lineage Cell Therapeutics
$1.06 /

+0.045 (+4.43%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.